GP-Act III Acquisition Corp. GPAT
Last close
10.97
2026-09-03
Market cap
—
52-week range
10.56 - 12.00
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| SG&A | $551.9K | $565.0K | $14.0K | — |
| Operating income | -$551.9K | -$565.0K | -$14.0K | — |
| Net income | $11.9M | $8.7M | -$14.0K | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $112.7K | $483.6K | $1.2K | $1.8K |
| Total current assets | $188.1K | $675.4K | $3.3K | — |
| Total assets | $309.4M | $297.5M | $530.2K | — |
| Total current liabilities | $634.6K | $631.6K | $628.2K | — |
| Total liabilities | $14.7M | $14.7M | $628.2K | — |
| Retained earnings | -$14.5M | -$13.9M | -$122.9K | — |
| Total equity | -$14.5M | -$13.9M | -$97.9K | -$83.9K |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$372.2K | -$584.7K | -$11.0K | — |
| Investing cash flow | — | -$287.5M | — | — |
| Financing cash flow | $1.3K | $288.6M | $10.4K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-034846.
Others in SIC 6770
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| DMII | Drugs Made In America Acquisition II Corp. | $647.8M | — | — |
| IACO | Idea Acquisition Corp. | $437.1M | — | — |
| KRAQ | KRAKacquisition Corp | $431.6M | — | — |
| TACO | Berto Acquisition Corp. | $393.6M | 36.2x | — |
| ALDF | Aldel Financial II Inc. | $322.7M | — | — |
| ATII | Archimedes Tech SPAC Partners II Co. | $315.1M | — | — |
| FGII | FG Imperii Acquisition Corp. | $289.7M | — | — |
| SOUL | Soulpower Acquisition Corp. | $268.0M | — | — |